Drug Trial Radar · NCT02345161
A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Jul 13, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,811
Actual
Start
Jan 23, 2015
Primary completion
Apr 1, 2016
Study completion Apr 7, 2016
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 26, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase IIIa, randomised, double-blind, double-dummy, parallel group multicenter study evaluating once daily FF/UMEC/VI (100 microgram \[mcg\]/62.5 mcg/25 mcg) inhalation powder versus twice daily budesonide/formoterol (400 mcg/12 mcg). The primary purpose of this study is to demonstrate improvements in lung function and health status for subjects treated with FF/UMEC/VI compared with budesonide/formoterol for 24 weeks. Once-daily 'closed' triple therapy of a Inhaled Corticosteroid/ Long-acting Muscarinic Receptor Antagonists/ Long Acting Beta-Agonist (ICS/LAMA/LABA) combination FF/UMEC/VI (100 mcg/62.5 mcg/25 mcg) in a single device is being developed with the aim of providing a new treatment option for the management of advanced (GOLD Group D) COPD which will reduce the exacerbation frequency, allow for a reduced burden of polypharmacy, convenience, and increase the potential for improvement in lung function, Health Related Quality of Life (HRQoL) and symptom control over established dual/monotherapies. Subjects meeting all inclusion/exclusion criteria and who have successfully completed all protocol procedures at the Screening Visit will enter the two-week run-in period. Following the run-in period, eligible subjects will be randomised (1:1) to one of the following double-blind treatment groups: FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg via the ELLIPTA™ dry powder inhaler (DPI) once daily in the morning and placebo via reservoir inhaler twice daily OR Budesonide/formoterol 400 mcg/12 mcg via reservoir inhaler twice daily and placebo via the ELLIPTA DPI once daily in the morning. The target enrollment is 1800 randomised subjects at approximately 200 study centers globally. The total duration of subject participation will be approximately 27 weeks, consisting of a 2-week run-in period, 24-week treatment period and a 1-week follow-up period. Subjects will run-in on their existing COPD medications for 2 weeks and in addition will be provided with short acting albuterol/salbutamol to be used on an as-needed basis (rescue medication) throughout the study. Subjects will discontinue all existing COPD medications during the randomised treatment period but may continue their study supplied rescue albuterol/salbutamol. A sub-set of approximately 400 subjects will remain on blinded study treatment for up to a total of 52 weeks to provide additional long term safety data. ELLIPTA and NUBULES are a trade marks of the GlaxoSmithKline Group of Companies. Other company or product names mentioned herein may be the property of their respective owners
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
Triple FF/UMEC/VIDrug
The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.
Placebo to match FF/UMEC/VIDrug
The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).
Budesonide/FormoterolDrug
The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.
Placebo to match Budesonide/Formoterol combinationDrug
The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.
Albuterol/salbutamolDrug
Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 24Time frame: Baseline to Week 24
- Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 52Time frame: Baseline to Week 52
- Change From Baseline in St George's Respiratory Questionnaire-Chronic Obstructive Pulmonary Disease (COPD; SGRQ) Total Score for COPD Participants at Week 24Time frame: Baseline to Week 24
- Change From Baseline in St George's Respiratory Questionnaire-COPD; SGRQ Total Score for COPD Participants at Week 52Time frame: Baseline to Week 52
Locations
159 sites in 15 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Dimitrovgrad, Bulgaria
GSK Investigational Site
Lovech, Bulgaria
GSK Investigational Site
Pleven, Bulgaria
GSK Investigational Site
Plovdiv, Bulgaria
GSK Investigational Site
Rousse, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Sofia, Bulgaria
GSK Investigational Site
Vidin, Bulgaria
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Chongqing, China
GSK Investigational Site
Wuxi, China
GSK Investigational Site
Guangzhou, Guangdong, China
GSK Investigational Site
Haikou, Hainan, China
GSK Investigational Site
Shenyang, Liaoning, China
GSK Investigational Site
Shenyang, Liaoning, China
GSK Investigational Site
Hangzhou, Zhejiang, China
GSK Investigational Site
Boskovice, Czechia
GSK Investigational Site
Brandýs nad Labem, Czechia
GSK Investigational Site
Cvikov, Czechia
GSK Investigational Site
Karlovy Vary, Czechia
GSK Investigational Site
Kralupy nad Vltavou, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Rokycany, Czechia
GSK Investigational Site
Tábor, Czechia
GSK Investigational Site
Teplice, Czechia
GSK Investigational Site
Haapsalu, Estonia
GSK Investigational Site
Kohtla-Järve, Estonia
GSK Investigational Site
Pärnu, Estonia
GSK Investigational Site
Tallinn, Estonia
GSK Investigational Site
Tallinn, Estonia
GSK Investigational Site
Tallinn, Estonia
GSK Investigational Site
Tallinn, Estonia
GSK Investigational Site
Tartu, Estonia
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Hamburg, Germany
Showing 40 of 159 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.